Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in HBV-related Hepatocellular Carcinoma
NCT03419481Phase 2Active, not recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Apr 2018
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Cambridge Clinical Trials Unit. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03419481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419481.